Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Advanced Gold Exploration Announces Private Placement (click to learn more) Nexera Energy Increases Ownership in Marpat Leases (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Chemomab Therapeutics Ltd CMMB

Healthcare Biotechnology
Chemomab Therapeutics Ltd, formerly known as Anchiano Therapeutics Ltd, is a Israel-based biopharmaceutical company. The Company specializes in the development of patient oriented targeted therapy for the treatment of a wide range of cancers. Its therapeutic and diagnostic technology, BC-819, constitutes a search paradigm for the targeted destruction of cancer cells with no effect on... see more

Recent & Breaking News (NDAQ:CMMB)

Chemomab Presentation at ACR Convergence 2023 Provides Further Support for Key Role of Its CCL24 Target in the Pathogenesis of Systemic Sclerosis

PR Newswire 12 days ago

Chemomab Therapeutics Receives FDA Fast Track Designation for CM-101 for the Treatment of Primary Sclerosing Cholangitis

PR Newswire 13 days ago

Chemomab Presents New Clinical Data Supporting CM-101's Anti-Fibrotic/Anti-Inflammatory Activity in Patients with Liver Fibrosis and New Data Highlighting Unique Association of Its CCL24 Target with Key PSC Pathways at AASLD's The Liver Meeting® 2023

PR Newswire November 13, 2023

Chemomab Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update

PR Newswire November 9, 2023

Chemomab Therapeutics Discloses Receipt of Nasdaq Notice Regarding Minimum Bid Price Requirement

PR Newswire November 6, 2023

Chemomab Therapeutics to Report Third Quarter 2023 Financial Results and Provide a Business Update

PR Newswire October 30, 2023

Chemomab Therapeutics to Present at Upcoming Scientific Conferences

PR Newswire October 26, 2023

Chemomab Therapeutics to Present Its CM-101 Clinical Program in Primary Sclerosing Cholangitis at 2023 Roth MKM Healthcare Opportunities Conference

PR Newswire September 28, 2023

Chemomab Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference

PR Newswire August 29, 2023

Chemomab Therapeutics Announces Second Quarter 2023 Financial Results and Provides a Corporate Update

PR Newswire August 14, 2023

Chemomab Therapeutics Announces Publication in JCI Insight Demonstrating Key Role of CCL24 in Primary Sclerosing Cholangitis

PR Newswire June 28, 2023

Chemomab Therapeutics Presents Data Reinforcing the Clinical Potential of CM-101 as a Novel Treatment for Primary Sclerosing Cholangitis at EASL 2023

PR Newswire June 26, 2023

Chemomab Therapeutics Reports Positive Data from Secondary Analysis of Phase 2a Liver Fibrosis Trial in NASH Patients at EASL 2023

PR Newswire June 21, 2023

Chemomab Therapeutics Announces Executive Leadership Changes and Provides a Corporate Update

PR Newswire June 5, 2023

Patient Data Presented at 2023 EULAR Congress Highlights How Serum CCL24 Levels Can Predict Vascular and Fibrotic Complications of Systemic Sclerosis

PR Newswire June 2, 2023

Chemomab Therapeutics to Participate in Upcoming Scientific Conferences

PR Newswire May 24, 2023

Chemomab Therapeutics Announces First Quarter 2023 Financial Results and Provides a Corporate Update

PR Newswire May 11, 2023

Chemomab Therapeutics to Present at 2023 Aegis Virtual Conference

PR Newswire April 26, 2023

Chemomab Therapeutics to Present at Upcoming Scientific Conferences

PR Newswire April 19, 2023

Chemomab Therapeutics to Discuss First Quarter 2023 Financial Results and Provide a Corporate Update

PR Newswire April 12, 2023